Astellas Announces Transfer of Qutenza™ to Grünenthal
TOKYO and CHERTSEY – 12 December, 2016: Astellas Pharma Inc. (President and
CEO: Yoshihiko Hatanaka, “Astellas”), today announced that Astellas Pharma Europe
Ltd. (“Astellas Pharma Europe”) has entered into a definitive agreement with
Grünenthal under which Astellas Pharma Europe will transfer the exclusive rights for
Qutenza™ (capsaicin 8% patch) in Europe, Middle East and Africa to Grünenthal.
Qutenza is approved by the European Medicines Agency (EMA) for the treatment of
peripheral neuropathic pain (PNP) in adults, and given Grünenthal’s heritage in the
therapy area, Astellas believes that patients will benefit from the continued access and
support this agreement ensures.
This agreement marks the start of a process that will see Astellas Pharma Europe
transfer all of its commercialisation rights for Qutenza to Grünenthal in all 28 European
Union member states, Switzerland, Iceland, Norway and Lichtenstein, and other
East European, Middle East and African countries. It is anticipated to conclude in
Until the transfer is complete, Astellas will continue to fully support the transition to
ensure that patients who rely on Qutenza for the management of their pain are
unaffected by this change.
Yukio Matsui, President of Operations, Astellas Pharma Europe commented: “This
agreement is a part of our work toward higher quality and efficiency of operations
through optimisation of resources and will ultimately provide hope for more patients
around the world. Grünenthal has a long track record in pain and will be well placed
to provide Qutenza to more patients who stand to benefit. We are looking forward to
working closely with Grünenthal to ensure smooth continuation of product supply.”
Gabriel Baertschi, CEO Grünenthal said: “We can look back on many successful
partnerships. This agreement is a perfect strategic fit for us, because it will
complement our existing business in the field of pain.”
Dott. Alberto Grua, member of the Corporate Executive Board, CCO Europe, North
America and Global Operations at Grünenthal added: “This product will give us the
opportunity to extend our portfolio in the neuropathic pain area. With our other pain
products, Grünenthal has built up a high level of expertise in this area, which will
allow us to market Qutenza successfully.”
Astellas reflected the impact from the transfer of Qutenza to Grünenthal in its current
fiscal year (from April 1, 2016 to March 31, 2017) financial forecast.
Notes to editors
About Qutenza (capsaicin 8% patch)
The capsaicin 8% patch which was developed by NeurogesX and licensed to Astellas Pharma Europe in 2009 is approved by the European Medicines Agency for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for pain.1 The capsaicin 8% patch is currently approved for use in 27 countries across Europe.
The capsaicin 8% patch delivers a high-dose of capsaicin directly to the damaged nerves in the skin that are the source of neuropathic pain. Applied to the area of pain, the capsaicin reduces their spontaneous activity and consequently reduces the neuropathic pain intensity.
Important information for the capsaicin 8% patch, including safety information, is included in the full Summary of Product Characteristics at: https://www.medicines.org.uk/emc/medicine/23156.
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.